Drugs / BI 2536
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02215044 | Jun 2007 → Dec 2008 | pancreatic neoplasm | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02211833 | Oct 2006 → Feb 2009 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00243087 | Jul 2005 → Aug 2008 | lymphoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02211859 | Aug 2004 → Dec 2007 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00526149 | Jul 2007 → Sep 2008 | breast cancer, cutaneous melanoma, endometrial cancer, head and neck cancer +2 | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00412880 | Feb 2007 → Jun 2008 | small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00701766 | Oct 2006 → Oct 2009 | acute myeloid leukemia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00706498 | Sep 2006 → Feb 2008 | prostate neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00710710 | Aug 2006 → Oct 2008 | pancreatic neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00376623 | Jul 2006 → Apr 2008 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 2536 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00243087 ↗ |
| Known as | KIN001-124 | ChEMBL registry synonym — accepted as the source's own label CHEMBL513909 ↗ |
| Known as | NPK33-1-98-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL513909 ↗ |
| Action | Inhibit | “BI 2536 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT00243087 ↗ |
| Modality | Small molecule | “BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1.” PMID 20471824 ↗ May 2010 |
| Route | Intravenous | “Patients receive BI 2536 IV over 1 hour on day 1.” NCT00243087 ↗ |
| Target | PLK1 | “BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1.” PMID 20471824 ↗ May 2010 |